Cargando…

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Huang, Qingying, Zhou, Yaoyao, He, Meizhi, Chen, Jianhong, Gao, Yubo, Wang, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354218/
https://www.ncbi.nlm.nih.gov/pubmed/30733677
http://dx.doi.org/10.3389/fphar.2018.01494
_version_ 1783391143672676352
author Li, Yan
Huang, Qingying
Zhou, Yaoyao
He, Meizhi
Chen, Jianhong
Gao, Yubo
Wang, Xue
author_facet Li, Yan
Huang, Qingying
Zhou, Yaoyao
He, Meizhi
Chen, Jianhong
Gao, Yubo
Wang, Xue
author_sort Li, Yan
collection PubMed
description Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains controversial. In this systematic review and meta-analysis, we aimed to evaluate the prognostic and clinicopathologic value of PD-L1 in PCa. Methods: We performed a systematic literature search in the PubMed, Cochrane Library, EMBASE, Web of Science, and SCOPUS databases up to July 21st, 2018. Pooled prevalence of PD-L1 in PCa was calculated using Freeman-Tukey double arcsine transformation by R software version 3.5.0. The data from the studies were examined by a meta-analysis using Review Manager software 5.3 to calculate pooled hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to estimate the prognostic and clinicopathologic value of PD-L1 in PCa. Heterogeneity was tested by the Chi-squared test and I(2) statistic. Results: Five studies with 2,272 patients were included in this meta-analysis. The pooled prevalence of PD-L1 in PCa was 35% (95% CI 0.32 to 0.37). Both PD-L1 expression (HR = 1.78; 95% CI 1.39 to 2.27; p < 0.00001) and PD-L1 DNA methylation (HR = 2.23; 95% CI 1.51 to 3.29; p < 0.0001) were significantly associated with poor biochemical recurrence-free survival (BCR-FS). PD-L1 tended to have high expression levels in high Gleason score cases (OR = 1.54; 95% CI, 1.17 to 2.03; P = 0.002) and androgen receptor-positive cases (OR = 2.42, 95% CI 1.31 to 4.50; P = 0.005). However, PD-L1 had relatively weak correlation with age, pathologic stage, lymph node metastasis and preoperative PSA level. Conclusions: This meta-analysis confirms the negative prognostic significance of PD-L1 expression and mPD-L1 in PCa patients. Additionally, PD-L1 has a statistically significant correlation with Gleason score and androgen receptor status, while the correlations with age, pathologic stage, lymph node metastasis, and preoperative PSA level were not statistically significant. However, the number of included studies is too small to make the conclusions more convincing, so more retrospective large-cohort studies are expected for the further confirmation of these findings.
format Online
Article
Text
id pubmed-6354218
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63542182019-02-07 The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis Li, Yan Huang, Qingying Zhou, Yaoyao He, Meizhi Chen, Jianhong Gao, Yubo Wang, Xue Front Pharmacol Pharmacology Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains controversial. In this systematic review and meta-analysis, we aimed to evaluate the prognostic and clinicopathologic value of PD-L1 in PCa. Methods: We performed a systematic literature search in the PubMed, Cochrane Library, EMBASE, Web of Science, and SCOPUS databases up to July 21st, 2018. Pooled prevalence of PD-L1 in PCa was calculated using Freeman-Tukey double arcsine transformation by R software version 3.5.0. The data from the studies were examined by a meta-analysis using Review Manager software 5.3 to calculate pooled hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to estimate the prognostic and clinicopathologic value of PD-L1 in PCa. Heterogeneity was tested by the Chi-squared test and I(2) statistic. Results: Five studies with 2,272 patients were included in this meta-analysis. The pooled prevalence of PD-L1 in PCa was 35% (95% CI 0.32 to 0.37). Both PD-L1 expression (HR = 1.78; 95% CI 1.39 to 2.27; p < 0.00001) and PD-L1 DNA methylation (HR = 2.23; 95% CI 1.51 to 3.29; p < 0.0001) were significantly associated with poor biochemical recurrence-free survival (BCR-FS). PD-L1 tended to have high expression levels in high Gleason score cases (OR = 1.54; 95% CI, 1.17 to 2.03; P = 0.002) and androgen receptor-positive cases (OR = 2.42, 95% CI 1.31 to 4.50; P = 0.005). However, PD-L1 had relatively weak correlation with age, pathologic stage, lymph node metastasis and preoperative PSA level. Conclusions: This meta-analysis confirms the negative prognostic significance of PD-L1 expression and mPD-L1 in PCa patients. Additionally, PD-L1 has a statistically significant correlation with Gleason score and androgen receptor status, while the correlations with age, pathologic stage, lymph node metastasis, and preoperative PSA level were not statistically significant. However, the number of included studies is too small to make the conclusions more convincing, so more retrospective large-cohort studies are expected for the further confirmation of these findings. Frontiers Media S.A. 2019-01-24 /pmc/articles/PMC6354218/ /pubmed/30733677 http://dx.doi.org/10.3389/fphar.2018.01494 Text en Copyright © 2019 Li, Huang, Zhou, He, Chen, Gao and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Yan
Huang, Qingying
Zhou, Yaoyao
He, Meizhi
Chen, Jianhong
Gao, Yubo
Wang, Xue
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
title The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
title_full The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
title_fullStr The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
title_full_unstemmed The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
title_short The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
title_sort clinicopathologic and prognostic significance of programmed cell death ligand 1 (pd-l1) expression in patients with prostate cancer: a systematic review and meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354218/
https://www.ncbi.nlm.nih.gov/pubmed/30733677
http://dx.doi.org/10.3389/fphar.2018.01494
work_keys_str_mv AT liyan theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT huangqingying theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT zhouyaoyao theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT hemeizhi theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT chenjianhong theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT gaoyubo theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT wangxue theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT liyan clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT huangqingying clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT zhouyaoyao clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT hemeizhi clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT chenjianhong clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT gaoyubo clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis
AT wangxue clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis